Disease relevance of Mycosis Fungoides

• Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia [1].
• We identified three patients with mycosis fungoides/Sézary syndrome that showed low density expression of the CD24-related epitope recognized by antibody BA-1 on circulating T cells [2].
• T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28 [3].
• Within the group of primary cutaneous T-cell lymphomas (CTCLs), mycosis fungoides (MF), Sézary's syndrome (SS), and CD30-positive lymphomas have been delineated as clinicopathological entities [4].
• In this study we examine the frequency and spectrum of P53 gene mutations in a large series of primary cutaneous lymphomas, with particular emphasis on tumor stage mycosis fungoides, as it is in these cases that p53 overexpression has previously been reported [5].

High impact information on Mycosis Fungoides

• Mycosis fungoides treated with acyclovir [6].
• Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study [7].
• To explore this possibility, we interviewed 174 patients with mycosis fungoides and 294 randomly selected control subjects in the San Francisco, Los Angeles, and Seattle areas concerning their lifetime histories of employment, chemical exposures, allergy, atopy, and certain medical conditions [8].
• The KS case rate among never-married men younger than 50 years old, a surrogate index of homosexuality, was found to be markedly elevated in the post-AIDS period, compared with the case rate of a reference disease, mycosis fungoides [9].
• Progression of mycosis fungoides during cimetidine therapy [10].

Chemical compound and disease context of Mycosis Fungoides

• Treatment of mycosis fungoides with isotretinoin [11].
• We have investigated the use of 2'-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF) [12].
• Cytogenetic analysis was performed on peripheral blood lymphocyte cultures from 19 patients with mycosis fungoides (MF)/Sézary syndrome (SS) stimulated with either phytohemagglutinin, a conventional mitogen, or a combination of interleukin-2 (IL-2) plus IL-7 [13].
• The technique of treatment, response rate, freedom from relapse, survival, and complications of therapy in 123 patients treated with topical nitrogen mustard (HN2) for cutaneous mycosis fungoides (MF) at Stanford University Medical Center are reviewed [14].
• Recently, in a Phase I study of the new alkylating agent temozolomide, two mycosis fungoides patients experienced a complete response [15].

Biological context of Mycosis Fungoides

• Furthermore, abnormalities of PTEN may be important in the pathogenesis of mycosis fungoides, but our data imply that this gene is rarely inactivated by small deletions or point mutations [16].
• Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides [17].
• To determine specific characteristics of Sezary cells that contribute to galectin-1 resistance, we assessed CD7 expression and cell surface glycosylation of Sezary cells in mycosis fungoides lesions and of four Sezary T cell lines [18].
• Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation [18].
• Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides [19].

Anatomical context of Mycosis Fungoides

• p19 Antigen in skin and lymph nodes of patient with advanced mycosis fungoides [20].
• p140/KIR3DL2 has been identified in malignant cell lines isolated from the skin and blood of patients with transformed mycosis fungoides (MF) and Sézary's syndrome (SS) [21].
• In situ hybridization experiments showed that interferon-gamma-inducible protein-9 mRNA is expressed by basal layer keratinocytes in a variety of skin disorders, including allergic contact dermatitis, lichen planus, and mycosis fungoides suggesting a functional role for this chemokine in skin immune responses [22].
• In the three cases with diffuse sheets without associated mycosis fungoides, the intensity of S-100 staining was the same in germinal centers as in parafollicular areas, while in cases associated with mycosis fungoides, the staining was predominantly in parafollicular zones [23].
• Evaluation of biopsy specimens for lymphocytes, eosinophils, nonlymphoid cell infiltration, epidermal lymphocytic exocytosis, mucin deposition, and epidermal hyperplasia revealed no predominant feature that differentiated the group with benign disease from the group with mycosis fungoides [24].

Gene context of Mycosis Fungoides

• CCR4 expression was also a consistent feature of the large-cell transformation of mycosis fungoides [25].
• Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA [26].
• In the tumor stage of mycosis fungoides, we interestingly observed a loss of a relevant chemokine receptor in four out of six patients [27].
• Here, we demonstrate extensive expression of CCR10 in skin biopsies of patients with Sezary syndrome (SS, n = 3), mycosis fungoides (MF, n = 2) and unspecified CTCL (n = 3) [28].
• Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides [29].

Analytical, diagnostic and therapeutic context of Mycosis Fungoides

• In this study skin biopsies from 17 CTCL patients, including 12 mycosis fungoides, four pleomorphic CTCL, and one CD8+ CTCL, were investigated for epidermal IL-8 and IP-10 mRNA expression by RNA in situ hybridization [30].
• We analyzed skin lesions from five patients with early mycosis fungoides using the polymerase chain reaction technique after microdissection of the specimens [31].
• Here, we studied signal transducers and activators of transcription (STAT) in patients with mycosis fungoides (MF)/cutaneous T-cell lymphoma (CTCL) [32].
• Viral infection, atopy and mycosis fungoides: a European multicentre case-control study [33].
• A combination of S-100 immunocytochemistry and morphologic ultrastructural assessment can be of help in evaluation of lymphadenopathy in patients with mycosis fungoides [23].

References